Description: Cardinal Health, Inc. (NYSE:CAH) is one of the stocks from different market sectors that Jim Cramer commented on. Cramer highlighted the company’s noteworthy performance, as he commented: “The drug distributors continue to relentlessly climb higher. There’s nothing, you know, people hate the pharma middleman. Even the president doesn’t talk, like… them. But I got to […]

Description: Cardinal Health, McKesson, and Cencora are showing how scale, specialty focus, and execution can drive market-beating returns despite macro pressure.

Description: Cencora (COR) shares have been relatively muted recently, with a 1-day decline of about 1% and a roughly flat return over the past month, even as the stock shows a strong total return over the past year. See our latest analysis for Cencora. The recent softness in Cencora’s share price, with the stock now at $335.74 and a small 90 day share price gain, contrasts with its much stronger 1 year and multi year total shareholder returns. This suggests momentum has cooled even as long term holders...

Description: Cencora is set to report its first-quarter earnings next month, and analysts are anticipating a single-digit increase in its bottom line.

Description: Cencora's strength in U.S. Healthcare Solutions, along with rising specialty drug demand and biosimilar adoption, supports growth, though competitive pressures and international weakness remain headwinds.

Description: CONSHOHOCKEN, Pa., January 06, 2026--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the First Quarter of Fiscal 2026 on Wednesday, February 4, 2026, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on February 4, 2026.

Description: McKesson posts a strong fiscal second quarter, lifts full-year EPS outlook, and shows how specialty growth and automation are reshaping its earnings power.

Description: Cencora (COR), McKesson (MCK), and Cardinal Health (CAH) performed strongly in 2025, and the drug di

Description: COO's revenues are showing strong growth as MyDay and MiSight drive momentum, while restructuring savings and buybacks bolster long-term upside despite near-term risks.

Description: Castle Biosciences surged 77.9% after a Zacks upgrade, highlighting how the firm's stock picks outpaced the broader market in recent months.

Description: GKOS appears well-positioned for long-term growth as iDose TR adoption accelerates and Epioxa secures FDA approval, although reimbursement and execution risks remain.

Description: BAX is reshaping its portfolio following the divestiture of Kidney Care, focusing on surgical strength, deleveraging and tighter execution to rebuild momentum.

Description: COR, ADUS and SEM earn bullish analyst support for 2026 as AI adoption, home care demand and facility expansion fuel medical sector growth.

Description: Merit Medical shows resilience despite 2025 share pressure, supported by cardiovascular growth, margin expansion and WRAPSODY CIE momentum.

Description: NVIDIA leads a group of stocks near 52-week highs, as Zacks highlights momentum-driven upside potential alongside Ralph Lauren, Expedia and Cencora.

Description: Stocks like NVDA, RL, EXPE and COR are seeing price strength and have a high chance of carrying the momentum forward.

Description: IRVINE, Calif., December 22, 2025--RIS Rx, a healthcare technology company offering gross-to-net (GTN) revenue protection and saving more than $1 billion for the world’s leading pharmaceutical manufacturers, today announced the appointment of Leslie Donato to its Board of Directors.

Description: Cencora, Inc. (NYSE:COR) is one of the stocks Jim Cramer recently discussed. During the lightning round, a caller inquired about Cramer’s thoughts on the stock, and he commented: “Okay, I like Cencora a lot. But I got to tell you, I think this Cardinal Health’s got them all beat. Jason Hollar is a visionary. I […]

Description: COR's $3.6 billion move to take control of OneOncology boosts its pharma-centric strategy and lifts its long-term growth outlook despite a short-term dip.

Description: If you are wondering whether Cencora's hot run still leaves room for value, you are not alone. That is exactly what we are going to unpack here. The stock has climbed 55.9% year to date and 53.6% over the last year, even after a recent 3.2% dip over the past month. This suggests the market is still recalibrating its view on the shares. Much of the recent interest in Cencora has been tied to its evolving role in the healthcare supply chain and strategic moves to strengthen its specialty...

Description: The drug distributor has been steadily building up its specialty support assets as it looks to increase access to drugs.

Description: Health care stocks rose late Monday afternoon with the NYSE Health Care Index gaining 1.2% and the S

Description: Health care stocks rose Monday afternoon, with the NYSE Health Care Index up 0.9% and the State Stre

Description: Cencora (COR) said Monday that it agreed to acquire majority of the stake it doesn't already own in

Description: Liquidia shares have surged 43.9% since an October upgrade, as Zacks highlights stock wins and portfolio results despite a volatile market.

Description: Cencora (COR) said Monday it has entered into a definitive agreement to acquire a majority of OneOnc

Description: Cencora, Inc. today announced it has entered into a definitive agreement to acquire TPG's equity interest in OneOncology, a physician-led national platform empowering independent medical specialty practices rooted in oncology. The transaction marks an important step for OneOncology and its practice partners, following significant physician-led investment and growth for the platform.

Description: CONSHOHOCKEN, Pa., December 15, 2025--Cencora, Inc. (NYSE: COR) today announced it has entered into a definitive agreement to acquire the majority of the outstanding equity interests that it does not currently own in OneOncology, a physician-led national platform empowering independent medical specialty practices rooted in oncology, from TPG, a leading global alternative asset management firm.

Description: Cencora recently announced it has expanded its global third-party logistics capabilities by acquiring NextPharma Logistics in Germany, Austria and Switzerland, investing in additional cold chain capacity across Europe, and committing to a new highly automated 500,000 square-foot 3PL facility in Texas expected to be operational in 2028. This build-out of temperature-controlled and cryogenic infrastructure deepens Cencora’s role in handling complex specialty medicines, positioning its...

Description: Cencora (COR) is back on investors radar after unveiling major upgrades to its third party and specialty logistics network in the United States and Europe, moves that neatly reinforce its improving earnings outlook. See our latest analysis for Cencora. The latest logistics expansion comes on the back of strong momentum, with a year to date share price return of 53.29% and a five year total shareholder return of 268.75%, suggesting investors are steadily repricing Cencora’s growth and...

Description: Cencora's U.S. Healthcare Solutions strength, RCA gains, and raised FY25 guidance underscore its accelerating growth momentum.

Description: Here is how Cencora (COR) and CorMedix (CRMD) have performed compared to their sector so far this year.

Description: Cencora (COR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Description: Shares of healthcare distributor Cencora (NYSE:COR) fell 4.3% in the afternoon session after analysts downgraded the company's stock to a "hold" rating from a "buy" a few days prior. This downgrade added to a negative trend for the stock, which had already fallen over the previous five trading sessions. The downward pressure from the new rating appeared to weigh on investor sentiment. The stock's performance reflected the market's reaction to the lowered expectations from the analyst firm.

Description: Cencora, Inc. (NYSE:COR) is included among the 15 Dividend Stocks that Outperform the S&P 500. On November 11, JP⁠Mor⁠gan raised its price t⁠arget on Cencora, Inc. (NYSE:COR) to $417 from $344 while mai‌ntaining an Overweight r‍ating, fo‌llowing an update to th⁠e comp⁠a⁠ny‌’s‌ f⁠inancial model. On November 5‌, Cencora, Inc. (NYSE:COR) announced pla‍ns to inves​t $1 […]

Description: CONSHOHOCKEN, Pa., December 03, 2025--Cencora, a global pharmaceutical solutions company, today announced investments to enhance its third-party logistics (3PL) capabilities in the United States and Europe, expanding its global network and strengthening the specialty logistics services it can deliver to pharmaceutical companies worldwide.

Description: While Cencora’s recent performance has lagged behind other healthcare stocks, analysts express strong confidence in its long-term growth potential.

Description: Cencora (COR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Description: MBX Biosciences' sharp rally highlights how Zacks' stock recommendations outpaced broader market gains across multiple portfolios.

Description: CVS posts a sharper MBR as PDR impacts ease and government business strengthens while maintaining a cautious full-year outlook.

Description: On November 25, 2025, Cencora Inc filed its annual 10-K report, detailing substantial financial growth and highlighting its acquisition of Alliance Healthcare to strengthen its global pharmaceutical distribution capabilities. The report also underscored Cencora's expanding opportunities in international markets and specialty pharmaceuticals, while noting increased operating expenses and ongoing litigation risks as important challenges. We'll now explore how Cencora's expanded international...

Description: Curious if Cencora stock still offers good value or if recent gains have pushed it out of reach? You are not alone in wondering whether now is the right time to take a closer look. Shares have been on the move, rising 2.2% in the past week and 64.0% year-to-date, building on an impressive 277.7% gain over the last five years. Recent headlines have highlighted Cencora’s expansive strategies, including major partnerships and sector-leading initiatives. These developments are fueling fresh...

Description: Cencora (COR) has shown a steady performance in recent weeks, catching the attention of investors who are watching for shifts in the healthcare distribution space. The stock’s trajectory offers an interesting lens into ongoing sector trends. See our latest analysis for Cencora. Cencora’s latest share price of $368.53 caps off an impressive run, with a 9.7% 1-month share price return and momentum continuing to build after recent sector tailwinds. Over the last year, shareholders enjoyed a...

Description: GE HealthCare unveils Genesis Radiology Workspace, aiming to streamline imaging workflows and boost diagnostic precision.

Description: Cencora (COR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Description: Here is how Cencora (COR) and Boston Scientific (BSX) have performed compared to their sector so far this year.

Description: Progyny (PGNY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Description: Macy's climbs after a Zacks upgrade as multiple portfolios showcase strong gains across UNFI, Monster Beverage and other standout stocks.

Description: Shares of Cencora (COR) have been catching the attention of investors recently, with the stock showing marked movement over the past month and more than doubling in value across the past three years. Recent trading reflects a generally positive trajectory and has prompted closer inspection of what might be driving this performance. See our latest analysis for Cencora. Cencora’s share price momentum has steadily increased, notching a 14.8% gain over the past month and climbing 62.45%...

Description: Investors signalled that they were pleased with Cencora, Inc.'s ( NYSE:COR ) most recent earnings report. Looking...

Description: Cencora’s third quarter saw a positive market response, as the company delivered revenue and non-GAAP earnings that exceeded Wall Street expectations. Management pointed to strong growth in its U.S. Healthcare Solutions segment and the contribution of specialty pharmaceuticals as key drivers. CEO Robert Mauch emphasized that investments in areas like specialty distribution and recent acquisitions, such as Retina Consultants of America, enhanced the company’s value to both pharmaceutical manufact

Description: Pharma distributor Cencora has continued to outpace the broader market over the past year, and analysts remain strongly bullish on the stock’s prospects.

Description: Cencora is betting on the future of pharmaceutical logistics, announcing a $1 billion investment through 2030 to expand and modernize its U.S. distribution infrastructure. This move is not just network growth, but a shift aimed at supporting the rising demand of prescription medications and strengthening the reliability of the supply chain that delivers them. The […] The post Cencora makes $1 billion investment in pharma supply chains appeared first on FreightWaves.

Description: The second national distribution centre, which is in Harrison, Ohio, will be operational by spring 2027.

Description: Cencora (COR) posted a net profit margin of 0.6%, a notch below last year’s 0.7%, while earnings rose 2.2% in the latest period, a significant slowdown from its 48.8% average annual growth rate over the past five years. Looking ahead, analysts expect earnings to increase by 11.04% per year, trailing the broader US market’s 16%, with the top line forecast to grow 6.7% versus the market’s 10.5%. However, the results were overshadowed by a one-off loss of $713.2 million in the trailing 12 months...

Description: Healthcare distributor Cencora (NYSE:COR) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 5.9% year on year to $83.73 billion. Its non-GAAP profit of $3.84 per share was 1.4% above analysts’ consensus estimates.

Description: Cencora Inc (COR) reports robust growth in adjusted income and EPS, while navigating goodwill impairments and strategic realignments.

Description: RGTI's Q3 results are likely to gain from U.S. funding clarity, new contracts and gains from its next-gen quantum system.

Description: Cencora's Q4 results top estimates with 15% EPS growth and stronger margins, as GLP-1 demand and the RCA acquisition fuel solid segment gains.

Description: Bennett S. Murphy: Thank you. Good morning, good afternoon, and thank you for joining us for this conference call to discuss Cencora, Inc.'s fiscal 2025 fourth quarter and full year results. Joining me today are Robert P. Mauch, President and CEO, and James F. Cleary, Executive Vice President and CFO.

Description: Although the revenue and EPS for Cencora (COR) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Description: Cencora (COR) delivered earnings and revenue surprises of +1.32% and +0.69%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Description: The company will open two new distribution centers and expand a third as demand surges for GLP-1s and other refrigerated medications.

Description: CONSHOHOCKEN, Pa., November 05, 2025--Cencora, a global pharmaceutical solutions company, today announced plans to invest $1 billion through 2030 to bolster and expand its pharmaceutical distribution network in the United States. The investments — headlined by the opening of its second national distribution center in Ohio and an expanded presence in Alabama and California — will increase Cencora’s capacity, improve efficiency and enhance the resilience of its national distribution network, stren

Description: Healthcare distributor Cencora (NYSE:COR) reported Q3 CY2025 results beating Wall Street’s revenue expectations, with sales up 5.9% year on year to $83.73 billion. Its non-GAAP profit of $3.84 per share was 1.4% above analysts’ consensus estimates.

Description: CONSHOHOCKEN, Pa. AP) — Cencora, Inc. COR) on Wednesday reported a loss of $339.7 million in its fiscal fourth quarter.

Description: CONSHOHOCKEN, Pa., November 05, 2025--Cencora, Inc. (NYSE: COR) today reported that in its fiscal year 2025 fourth quarter ended September 30, 2025, revenue increased 5.9 percent to $83.7 billion. Revenue increased 9.3 percent to $321.3 billion for fiscal year 2025. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $(1.75) for the September quarter of fiscal 2025, compared to $0.02 in the prior year quarter. Adjusted diluted EPS, which is

Description: Agilon (AGL) delivered earnings and revenue surprises of -50.00% and +0.57%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Description: Solventum's Q3 results may reflect softer sales and tariff impacts, though pricing discipline and core growth drivers likely aided margins.

Description: Dentsply Sirona's Q3 results may reveal ongoing softness in U.S. demand and orthodontic segments despite steady cost control.

Description: McKesson's Q2 results may show steadier growth as strong U.S. pharmaceutical and RxTS momentum drive its expanding top line.

Description: Healthcare distributor Cencora (NYSE:COR) will be reporting earnings this Wednesday before the bell. Here’s what you need to know.

Description: Humana, Cencora and Globus Medical are poised to outshine in the September quarter, driven by strong demand, innovation and volume growth.

Description: Evaluate the expected performance of Cencora (COR) for the quarter ended September 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Description: Check out the companies making headlines this week:

Description: Shares of healthcare distributor Cencora (NYSE:COR) jumped 3.3% in the morning session after Mizuho analyst Steven Valiquette raised the price target on the company's shares. The price target was increased to $340 from $334, while the firm kept an 'Outperform' rating on the stock. This move signaled continued confidence in Cencora's market performance. Adding to the positive mood in the sector, a key peer, Cardinal Health, reported strong quarterly results and lifted its outlook for the year. Ca

Description: Viatris (VTRS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Description: Cencora (COR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Description: The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Description: Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Description: Baxter's Q3 results are expected to show steady revenue growth led by Advanced Surgery and Drug Compounding, though IV fluid and anesthesia softness may weigh on EPS.

Description: The U.S. Cell and Gene Therapy Third-Party Logistics (3PL) Market is anticipated to surge from US$ 2.61 billion in 2024 to US$ 5.88 billion by 2033, maintaining a CAGR of 9.46% from 2025 to 2033. Key growth drivers include increased therapy adoption, specialized logistics needs, and expanding biopharmaceutical collaborations. Regulatory demands, cold chain technology adoption, and challenges such as logistics costs and workforce expertise underscore the market's evolution. States like California

Description: DentScribe.ai, the agentic AI platform that transforms dental SOAP notes into real-time clinical checklists and practice growth signals, today announced that Dr. Mandeep S. Dhalla, MD, has invested in the company and joined as a Strategic Advisor.

Description: Cencora (COR) shares continue to climb, gaining around 1% in the past day and up over 8% for the month. Investors seem to be weighing the company’s strong revenue and net income growth in light of broader market trends. See our latest analysis for Cencora. Cencora’s momentum is clearly building, with a 1-month share price return of 8% and the stock now up over 48% year to date. Its 1-year total shareholder return of 43% is even more impressive, reinforcing both near-term optimism and the...

Description: CAH's Pharmaceutical and Specialty units are expected to have fueled double-digit revenue growth in Q1 FY26 despite tariff and cost headwinds.

Description: UHS is likely to have posted Q3 revenue and earnings growth, driven by strong hospital and behavioral health segments despite cost pressures.

Description: Cencora is scheduled to release its fourth-quarter results next month, with analysts projecting double-digit earnings growth.

Description: Cencora (COR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Description: Earlier this week, Cycle Pharmaceuticals announced the launch of PHYRAGO, a new oncology therapy for leukemia, developed with Handa Therapeutics and made exclusively available in the US through Onco360® and a specialty distribution network that includes McKesson. This collaboration provides McKesson with a valuable commercial opportunity as an exclusive distributor for a newly introduced specialty oncology product in high-need therapeutic areas. We'll explore how McKesson's participation in...